Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of BCAT1 inhibition on activated human CD8+ T cells

ABSTRACT: Branched chain amino acid transaminase 1 (BCAT1) moderates iron balance during CD8+ T cell activation by limiting the conversion of iron regulatory protein 1 (IRP1) to aconitase 1 (ACO1). BCAT1 inhibition (BCAT1i) increases ACO1 activity, prevents iron uptake by activated CD8+ T cells, increases iron-sulfur (Fe-S) clusters in the mitochondria, arrests the timely degradation of nuclear ACO1, and inhibits CD8+ T cell differentiation in vitro and in vivo. The effects of BCAT1i on CD8+ T cell activation include upregulation of genes associated with DNA damage response and pro- and anti-apoptotic pathways and downregulation of genes involved in cell cycling, DNA replication, mRNA splicing, and ribosome biogenesis. The majority of the affected processes require iron as a co-factor.

ORGANISM(S): Homo sapiens

PROVIDER: GSE261260 | GEO | 2026/02/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The effect of temporal BCAT1 inhibition on activated human CD8+ T cells

Project description:Branched chain amino acid transaminase 1 (BCAT1) moderates iron balance during CD8+ T cell activation by limiting the conversion of iron regulatory protein 1 (IRP1) to aconitase 1 (ACO1). BCAT1 inhibition (BCAT1i) increases ACO1 activity, prevents iron uptake by activated CD8+ T cells, increases iron-sulfur (Fe-S) clusters in the mitochondria, arrests the timely degradation of nuclear ACO1, and inhibits CD8+ T cell differentiation in vitro and in vivo. The effects of BCAT1i on CD8+ T cell activation are reversible and temporal BCAT1i yields CD8+ T cells with increased effector functions. CD8+ T cells, which were activated in the presence of ERG245 (BCAT1 inhibitor) for 24h and cultured for an additional 48h without it, upregulated genes that support bioenergetics processes such as OXPHOS, glycolysis, FA metabolism.

2026-02-24 | GSE261261 | GEO

BCAT1 expression associates with ovarian cancer progression

Project description:Previously, we have identified cytosolic form of the branched chain amino-acid transaminase 1 (BCAT1) as notably hypomethylated in low-malignant potential (LMP) and high-grade (HG) serous epithelial ovarian tumors, compared to normal ovarian tissues. Here we show that BCAT1 is strongly overexpressed in both LMP and HG serous EOC tumors, thus suggesting that epigenetic mechanisms might be implicated in BCAT1 overexpression in serous epithelial ovarian cancer (EOC). Knockdown of the BCAT1 expression in EOC cells led to sharp decrease of cell proliferation and induced S-phase cell cycle arrest. Additionally, BCAT1 suppression significantly inhibited EOC cell migration and invasion. Gene expression profiling and consecutive network and pathway analyses confirmed these findings, as numerous genes and pathways known previously to be implicated in ovarian tumorigenesis, including EOC tumor invasion and metastasis, were found to be downregulated upon BCAT1 suppression, while some tumor suppressor genes were induced. Taken together, our data are indicative for a strong oncogenic potential of the BCAT1 gene in advanced EOC and identify this transaminase as a novel EOC biomarker and putative EOC therapeutic target.

2015-10-01 | GSE64424 | GEO

BCAT1 contributes to the developmentproliferation and leukemogenesis of TKI-resistant CML

Project description:In this report, we revealed that branched chain amino acid transaminase 1 (BCAT1) is highly enriched in both mouse and human TKI-resistant CML cells. Leukemia was almost completely abrogated upon BCAT1 knockdown during transplantation in a BCR-ABLT315I-induced murine TKI-resistant CML model . Moreover, knockdown of BCAT1 led to a dramatic decrease in the proliferation of TKI-resistant human leukemia cell lines. BCAA/BCAT1 signaling enhanced the phosphorylation of CREB, which is required for maintenance of TKI-resistant CML cells. Importantly, blockade of BCAA/BCAT1 signaling efficiently inhibited leukemogenesis both in vivo and in vitro.

2024-05-30 | GSE262421 | GEO

Effect of BCAT1 depletion on sensitivity to Etoposide in T-cell acute lymphoblastic leukemia cells

2025-01-02 | GSE275161 | GEO

BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression

Project description:Glioblastoma is the most common malignant brain tumor in adults. Cellular plasticity and the poorly differentiated features result in a fast relapse of the tumors following treatment. Moreover, the immunosuppressive microenvironment proved to be a major obstacle to immunotherapeutic approaches. Branched-chain amino acid transaminase 1 (BCAT1) is a metabolic enzyme that converts branched-chain amino acids into branched-chain keto acids, depleting cellular α-ketoglutarate and producing glutamate. BCAT1 was shown to drive the growth of glioblastoma and other cancers; however, its oncogenic mechanism remains poorly understood. Here, we show that BCAT1 is crucial for maintaining the poorly differentiated state of glioblastoma cells and that its low expression correlates with a more differentiated glioblastoma phenotype. Furthermore, orthotopic tumor injection into immunocompetent mice demonstrated that the brain microenvironment is sufficient to induce differentiation of Bcat1-KO tumors in vivo. We link the transition to a differentiated cell state to the increased activity of TET demethylases and the hypomethylation and activation of neuronal differentiation genes. In addition, the knockout of Bcat1 attenuated immunosuppression, allowing for an extensive infiltration of CD8 + cytotoxic T-cells and complete abrogation of tumor growth. Further analysis in immunodeficient mice revealed that both tumor cell differentiation and immunomodulation following BCAT1-KO contribute to the long-term suppression of tumor growth. In summary, our study unveils BCAT1's pivotal role in promoting glioblastoma growth by inhibiting tumor cell differentiation and sustaining an immunosuppressive milieu. These findings offer a novel therapeutic avenue for targeting glioblastoma through the inhibition of BCAT1.

2024-11-08 | GSE247299 | GEO

Both enzymatic and non-enzymatic functions of BCAT1 confer malignant properties in human chondrosarcoma

Project description:Human chondrosarcoma is a malignant bone tumor with a poor prognosis due to its resistance to conventional therapies. In this study, we investigated the role of Branched-Chain Amino Acid Transaminase 1 (BCAT1) in chondrosarcoma pathogenesis.

2026-01-01 | GSE303334 | GEO

Effect of depletion of BCAT1 on gene expression during NOTCH1-dependent leukemia development in the mouse

Project description:High levels of branched-chain amino acid (BCAA) transaminase 1 (Bcat1) have been associated with adverse prognosis and drug resistance in several cancer types. However, the mechanistic role of Bcat1 in T-cell acute lymphoblastic leukemia (T-ALL) development is ill defined. Here, we used a mouse T-ALL model to show that Bcat1 is required for T-ALL development and maintenance. Using a NOTCH1 gain-of-function retroviral model of T-ALL, mouse cells genetically deficient for Bcat1 showed defects in developing leukemia. Amongst the pathways upregulated in Bcat1 KO delta E-NOTCH1 cells we found “DNA repair”, “apoptosis”, and “p53 pathway”. We thus hypothesize that Bcat1 may be implicated in cell cycle progression or apoptosis of T-ALL cells.

2024-09-01 | GSE267966 | GEO

Lack of the pif1 helicase enhances zinc tolerance in S. cerevisiae

Project description:The Saccharomyces cerevisiae gene PIF1 encodes a conserved eukaryotic DNA helicase required for both mitochondrial and nuclear DNA integrity. Our previous work revealed that a pif1D strain is tolerant to zinc overload. We demonstrate here that this effect is independent of the Pif1 helicase activity and is only observed when the protein is absent from the mitochondria. pif1 cells accumulate abnormal amounts of mitochondrial zinc and iron. Transcriptional profiling reveals that pif1 cells under standard growth conditions overexpress aconitase-related genes. When exposed to zinc, pif1 cells show lower induction of genes encoding iron (siderophores) transporters and higher expression of genes related to oxidative stress responses than wild type cells. Coincidently, pif1 mutants are less prone to zinc-induced oxidative stress and display a higher reduced/oxidized glutathione ratio. Strikingly, although pif1 cells contain normal amounts of the Aco1 protein, they completely lack aconitase activity. Loss of Aco1 activity is also observed when the cell expresses a non-mitochondrially targeted form of Pif1. We postulate that lack of Pif1 forces aconitase to play its DNA protective role as nucleoid protein and that this would trigger a domino effect on iron homeostasis resulting in increased zinc tolerance.

2010-06-01 | GSE18411 | GEO

Identification of potential interacting proteins for Drosophila IRP1A, IRP1B, AGBE

Project description:In an effort to understand the relationship between iron homeostasis and glycogen synthesis in Drosophila, we performed mass spectrometry to identify any candidate interact with IRP1A or IRP1B, the Drosophila orthologs of human IRP1/Aco1 as well as AGBE, the Drosophila ortholog of human GBE1.

2019-10-10 | PXD013499 | Pride

BCAT1-Mediated N-Myc Stabilization Contributes to Tumorigenesis of MYCN-Amplified Neuroblastoma

Project description:Neuroblastoma (NB) is a common neuroendocrine tumor in early childhood, and the poor prognosis of high-risk NB is due to its poorly differentiated characteristics and immunosuppressive microenvironment. Around 25% of high-risk NB in children is caused by MYCN gene amplification. In this study, we found that Branched-chain amino acid transaminase 1 (BCAT1) is overexpressed in NB, especially those with MYCN amplification, and is a positively correlated with MYCN expression. Moreover, BCAT1 may be a risk factor for NB, significantly affecting proliferation of NB cells. Besides, we revealed that MYCN directly regulated BCAT1 transcription through binding to BCAT1 promoter, thus enhancing BCAT1-MYCN cooperativity. The highly disordered loop region of the MYCN protein makes it readily degraded under natural conditions, making it difficult to obtain the real structure of MYCN through experiments. We performed GROMACs optimization on the MYCN structure obtained from Alphafold, which increased the reliability of the MYCN structure and met the requirements of subsequent protein docking experiments. In this study, we found that after BCAT1 binds to the disordered regions of MYCN, it can improve the overall stability of MYCN. Therefore, we hypothesized that BCAT1 can enhance the stability of MYCN, suggesting that BCAT1 may be a potential therapeutic target for MYCN-amplified NB. In summary, these findings establish BCAT1 is a critical oncogenic factor in NB and provide a new potential target for treatment of NB with MYCN amplification.

2025-04-01 | GSE267875 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data